COVID-19 outcomes in patients with a history of immune-mediated glomerular diseases.

Patients with immune-mediated glomerular diseases are considered at high risk for severe COVID-19 outcomes. However, conclusive evidence for this patient population is scarce. We created a global registry and retrospectively collected clinical data of patients with COVID-19 and a previously diagnosed immune-mediated glomerular disease to characterize specific risk factors for severe COVID-19 outcomes. Fifty-nine patients with a history of immune-mediated glomerular diseases were diagnosed with COVID-19 between 01.03.2020 and 31.08.2021. Over a mean follow-up period of 24.79 ± 18.89 days, ten patients (16.9%) developed acute kidney injury. Overall, 44.1% of patients were managed in an outpatient setting and therefore considered as having "non-severe" COVID-19, while 55.9% of patients had severe COVID-19 requiring hospitalization including worse outcomes. Comparing both groups, patients with severe COVID-19 were significantly older (53.55 ± 17.91 versus 39.77 ± 14.95 years, p = .003), had lower serum albumin levels at presentation (3.00 ± 0.80 g/dL versus 3.99 ± 0.68 g/dL, p = .016) and had a higher risk of developing acute kidney injury (27% versus 4%, p = .018). Male sex (p <.001) and ongoing intake of corticosteroids at presentation (p = .047) were also significantly associated with severe COVID-19 outcomes, while the overall use of ongoing immunosuppressive agents and glomerular disease remission status showed no significant association with the severity of COVID-19 (p = .430 and p = .326, respectively). Older age, male sex, ongoing intake of corticosteroids and lower serum albumin levels at presentation were identified as risk factors for severe COVID-19 outcomes in patients with a history of various immune-mediated glomerular diseases.

Informations de copyright

Copyright © 2023 Gauckler, Kesenheimer, Geetha, Odler, Eller, Laboux, Alberici, Zappa, Chebotareva, Moiseev, Bonilla, Jhaveri, Oniszczuk, Audard, Costa, Mastroianni-Kirsztajn, Bruchfeld, Muto, Windpessl, Mayer and Kronbichler.

Déclaration de conflit d'intérêts

PG received consulting fees from CLS Vifor and lecture fees from Otsuka Pharma GmbH. AK received grants from CSL Vifor and Otsuka, consulting fees from CSL Vifor, Otsuka, Walden Biosciences and Catalyst Biosciences, honoraria for lectures from CSL Vifor and Otsuka and support for attending meetings from CSL Vifor and Otsuka. DG received consulting fees from ChemoCentryx, Amgen, Otsuka, Aurinia Inc and GSK. BO reports receiving fees or research grants from CSL Vifor, Otsuka and Delta4. FA received consulting fees and honoraria for lectures from AstraZeneca. AB received consulting fees and honoraria for lectures from AstraZeneca, Bayer, ChemoCentryx, Fresenius, Merck/MSD, and Vifor and received payment for expert testimony from The Swedish National Board of Health and Welfare and chaired the Immunonephrology Working Group of ERA unpaid. VA received supporting attending meetings from Sanofi Genzyme, and reports board participations for Alnylam, Addmedica, AstraZeneca, Bayer and ViforPharma. KJ received consulting fees from GlaxoSmithKline, George Clinical, PMV Pharmaceuticals and Caliditas and honoraria for lectures from ASN and uptodate.com. MW received honoraria for lectures from Otsuka and participated on advisory boards for Otsuka, Delta4 and CSL Vifor. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.